Eungyosan

PreclinicalSmall molecule

KKorean Medicine Hospital of Pusan National University

Eungyosan is one of 29 small molecule programs targeting Common Cold. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Common ColdActive, not recruiting

Common ColdPreclinical

Active, not recruiting

Competition

Competitive Landscape

51 competitors in Common Cold

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

1 2

Aleve

Alnylam Pharmaceuticals

Paracetamol

7 4

Acetylsalicylic Acid

Bayer

Approved

3 5

Advil

Tylenol

Vivarin

HHikma Pharmaceuticals LLC

Clarinex

Test

RRespirent Pharmaceuticals Co Ltd.

Approved

1 10

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Common Cold1 trial

Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold

Unknown status·KKorean Medicine Hospital of Pusan National University·N/A·NCT04073511·375 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Eungyosan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eungyosan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eungyosan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korean Medicine Hospital of Pusan National University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKorean Medicine Hospital of Pusan National University

Eungyosan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Common Cold1 trial

References

Drug Info

Quick Facts

Related News